Webinar Details:

FDA's March 2026 draft guidance (Docket No. FDA-2025-D- 1504) marks the Agency's first standalone document dedicated specifically to how establishments should respond to a Form 483 following a drug CGMP inspection. This presentation translates that guidance into a practical playbook for Quality, Regulatory Affairs, and site leadership teams preparing for or recovering from an inspection.

This presentation is organized in five parts. Part 1 explains what a Form 483 is, how it differs from a Warning Letter, and why FDA issued the guidance — namely, a recurring pattern of incomplete, unfocused, or root-cause-avoidant responses that hampered the Agency's ability to evaluate remediation. Part 2 details the required response format under Section III: establishment identity, a copy of the 483, preparer and signatory identification, an executive summary table, per-observation discussion, translation requirements, interim reporting expectations, submission channels, and the critical 15-business- day response window. Part 3 covers Section IV's substantive recommendations — prioritizing and clustering observations, engaging consultants where warranted, assigning management responsibility, building investigation teams and plans, conducting root-cause analysis, and developing and evaluating CAPA effectiveness. Part 4 addresses Section V's process for raising scientific or technical disagreements with FDA's findings.

The presentation closes with a practical synthesis — common reasons FDA rejects 483 responses and a readiness checklist — followed by an appendix of five real 2025–2026 Warning Letter case studies (Fareva Morton Grove, Simtra BioPharma, Tentamus India, Medline, and Purolea Cosmetics) illustrating the guidance's principles in enforcement practice, including FDA's first-ever citation for inappropriate AI use in CGMP documentation.

Key takeaway: A credible 483 response must be timely, consolidated, and demonstrably address root cause and systemic scope — not merely the literal wording of the cited observation — with visible executive management accountability throughout.

Fee:
$385 for one person
$700 2-5 people
$999 6-10 people

Register for ECC-765